Cold atmospheric pressure plasma for treatment of chronic wounds: drug or medical device? by Kramer, Axel et al.
Journal of Wound Care
 
Cold atmospheric pressure plasma for treatment of chronic wounds: drug or medical
device?
--Manuscript Draft--
 
Manuscript Number: jowc.2016.0161R1
Full Title: Cold atmospheric pressure plasma for treatment of chronic wounds: drug or medical
device?
Article Type: Comment/Opinion
Keywords: cold atmospheric pressure plasmas, features of action, medical device, medical drug
Corresponding Author: Ojan Assadian, MD, DTMH
Medizinische Universitat Wien
Vienna, AUSTRIA
Corresponding Author Secondary
Information:
Corresponding Author's Institution: Medizinische Universitat Wien
Corresponding Author's Secondary
Institution:
First Author: Axel Kramer, MD, PhD
First Author Secondary Information:
Order of Authors: Axel Kramer, MD, PhD
Barbara R Conway, PhD
Konrad Meissner, MD, PhD
Fritz Scholz, PhD
B H Rauch, PhD
Anke Moroder
Alexander Ehlers
Alfred J. Meixner, PhD
Claus-Dieter Heidecke, MD, PhD
Lars Ivo Partecke, MD
Manfred Kietzmann, PhD
Ojan Assadian, MD, DTMH
Order of Authors Secondary Information:
Response to Reviewers: Authors‘ Reply to Reviewer comments
Ref.:  Ms. No. jowc.2016.0161
Cold atmospheric pressure plasma for treatment of chronic wounds: drug or medical
device?
Journal of Wound Care
I would be grateful if you could highlight the changes you have made to the text in
yellow (not using tracked changes) and include a summary of the revisions you have
made when you resubmit your article.
Reviewer #1
C1.In Germany, the society for plasma-medicine has recently undertaken activities to
implement a standard for regulation of plasma devices, the DIN SPEC 91315. It is
recommended to include this in the discussion.
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
A1: We sincerely thank the respected reviewer for pointing out to this important
standard. We have included now a brief statement highlighting the DIN SPEC 91315,
and we have added the standard’s reference to the reference list. The added
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Abstract 
Background. The use of cold atmospheric pressure plasmas (CAPs) as a new therapeutic 
option for chronic wounds appears to be promising. Currently, uncertainty exists regarding 
their classification as medical device or medical drug.  
Objective. Because the classification of CAP has medical, legal, and economic 
consequences as well as implications for the level of pre-clinical and clinical testing, the 
correct clarification is not an academic debate, but an ethical need. 
Method. A multidisciplinary team of researchers and lawyers has analyzed the physical and 
technical characteristics as well as legal conditions of the biological action of CAP. 
Results. It is concluded that the mode of action of the locally generated CAP with its main 
active components, being different radicals, is pharmacological and not physical in nature. 
Conclusion. Depending on the intended use, CAP should be classified as a drug, which is 
generated by use of a medical device directly at the point of therapeutic application. 
Abstract Click here to download Anonymous manuscript 2-
Abstract.docx
 1 
Background 
Highly energetic physical plasmas comprise a mixture of reactive ionized particles, which can 
be physically adjusted to body temperature by mixing protons, resulting in so-called “cold 
plasma”. Cold atmospheric pressure plasmas (CAPs) are generated under atmospheric 
pressure at ambient temperatures ranging from 20°C to 50°C.1, 2 
Interest in medical applications of CAPs is rapidly increasing. CAPs ignited a technological 
spark in industry, biotechnology, and in the field of hygiene, for indications where the use of 
antimicrobial active agents or heat sterilization is limited. This includes decontamination of 
thermo-labile medical devices, food, packaging materials, waste-water, or indoor air.3 For 
such applications, the question does not arise whether CAPs are a drug or a medical device. 
On the other hand, plasma has shown promising antiseptic results on skin and mucosal 
membranes in infection-related diseases in dermatology4-6 and dentistry7, and has also been 
found to exert anti-carcinogenic effects similar to those of oxygen radicals, mainly by dose-
dependent anti-proliferative8 and apoptotic activity.9-13 First reports on the use of argon 
plasma for tumor removal date back to 198914, followed by successful ablation of non-
neoplastic Barrett's mucosa15 and other neoplastic diseases.16-21 A plasma-activated medium 
has even been claimed to exert anti-tumor effects.22, 23  
Results of in-vitro,24 in-vivo24-28 and initial clinical studies on chronic wounds of domestic 
animals29, 30 and humans31-35 indicate that CAP may be a promising alternative to 
conventional treatment options, based on the following biological premises: 
- A wound cannot heal as long as it is infected36. CAP may support wound healing 
through its antiseptic efficacy in vitro37-39, ex vivo40, in vivo41 and in humans.31, 32, 42-44 
- CAP may facilitate the transformation of the chronic wound from a stagnating wound 
to an acute healing wound, i.e. by inflammatory45,46 and proliferation-supporting 
stimuli 47,48, including stimulation of neovascularization.29,49,50 
However, while the medical applications of CAP are promising, it is vital to ensure the safety 
and reliability of applied CAPs in humans before it may be considered for routine clinical 
Anonymous manuscript R1 Click here to download Anonymous manuscript Manuscript
R1.docx
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practice. Therefore, aside from the clinical effectiveness, the safety for patients and users is 
an important consideration during the registration and approval processes with health 
authorities. Based on the intended use and the potential risks associated with a medical 
intervention, be it supportive, diagnostic, or therapeutic, products may be classified as 
medical devices, or medical drugs. 
In this respect and as a first step, the technical standard DIN SPEC 91315:2014-06 was 
developed, which characterizes the basic physical and technical performance parameters of 
CAP sources to be used for bio-medical or biological experiments and for further 
development to become medically applicable plasma sources.51 However, findings on 
mutagenicity52-54 and transient expression of pre-mutagenic active compounds, even though 
the latter was as result of directly exposing DNA 55, suggest that the current risk assessment 
for plasma applications is still incomplete and there is a need to consider also energy, 
penetration depth, and the body’s detoxification capacity must also be considered. In addition 
to classification issues, both pre-clinical and clinical investigations need to be preceded by 
tests of clinical effectiveness and the exclusion of chronically toxic, mutagenic, and 
carcinogenic risks. 
The final decision on the correct classification of CAP has not only medical, legal, and 
economic consequences, but also fundamental implications for the required level of pre-
clinical testing, and future development of this new technology. To date, the final 
classification of CAPs as a medical drug or medical device has been the subject of academic 
debate, resulting in uncertainty on the required test data for registration with the respective 
health authorities in Europe and the US, product liability, manufacturers’ responsibility, and 
future economic strategies. Therefore, a multidisciplinary team of physicians, surgeons, 
pharmacists, physicists, and lawyers familiar with the medical application of CAPs has 
critically evaluated the requirements for the classification of cold atmospheric pressure 
plasmas as a medical drugs or medical devices from different perspectives.  
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Differentiation between drug and medical device 
In Europe and the US, medical drugs and medical devices are regulated by separate laws, 
which cannot be applied simultaneously. Dual labeling is generally not accepted by drug 
administration agencies and thus entities are regulated by either the medical devices or 
medicines legislation, but not both. Historically, medical drugs were distinguished from 
medical devices by their pharmacological, metabolic, and/or immunologic effects, while the 
mode of action of medical devices was predominately based on physical aspects. 
Furthermore, based on the potential risk associated with the use of medical devices, they 
can be distinguished into 3 classes. Class I medical devices are defined as devices without 
risks to humans due to low invasiveness, temporary use (≤ 60 min), and application with non-
critical skin contact. Class IIa medical devices bear potential risks as they are associated 
with moderate invasiveness, short-term uninterrupted or repeated use (≤ 30 d) within the 
human body (ophthalmological, intestinal, or surgically created body cavities). Class IIb 
medical devices have potential elevated risks, elicit systemic effects, or are intended for use 
beyond 30 days (i.e. non-invasive birth control). Finally, class III medical devices have the 
highest potential risks, e.g. technical solutions for long-term drug application, pacemakers, 
implants, or invasive birth control devices. 
However, the intention of preventing or treating illnesses may apply to both medical drugs 
and medical devices, and therefore does not qualify as a distinguishing characteristic 
between the two. Thus, the only reason to objectively differentiate between a drug and a 
medical device is its pharmacologic, immunologic or metabolic effect, compared to the 
physical effect of the medical device, which may merely support pharmacologic, immunologic 
or metabolic effects. Pertaining to CAP devices, their categorization as drugs or medical 
devices therefore depends solely on their mode of action. For example, surgical CAP devices 
used for cutting or coagulating tissue in humans (so-called “beamers”) 56 or plasma skin 
regeneration devices 57, were previously approved as medical devices class IIb, and based 
on their physical (thermal) mode of action. 
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In contrast, the MEDDEV-Borderline guideline58 defines a pharmacologic effect as an 
interaction between molecules of the substance in question and a cellular component, such 
as a receptor, which either elicits a direct response or blocks another one in response to a 
third agent. The view therefore does not specifically demand an interaction of substance 
molecules with “cellular components of the host”, but merely requires “cellular components” 
only. A recent decision of the European Court 59 supports the definition of a pharmacologic 
effect of a substance as an interaction with any cellular components within the host’s body, 
including foreign targets cells like bacteria, viruses, or parasites. This opinion is also 
supported by the European directive 2004/27/EG, a revised version of the directive 
2001/83/EG section 2, subsection 2, which elevates the MEDDEV-Borderline guideline58 to 
the instrument of choice in cases of uncertainty for defining a new technology. 
However, where pharmacological aspects outweigh the physical therapeutic use of CAP, its 
classification requires a more complex consideration. In the case of CAP, the transferability 
of obvious physical and biological effects between different CAP devices is complex due to 
various potential mixtures of reactive species and the application of energy during plasma 
application.  
 
Physical and chemical characteristics of CAP 
The different available technologies relevant for plasma medicine can be categorized either 
as direct or indirect physical plasmas. In the case of direct plasmas, the patient’s body 
serves as the second electrode through an electric voltage field between the head of the 
device and the skin surface to be treated, i.e. dielectrically impaired discharges (DBE).60,61 
Indirect plasmas (plasma jets) arise between two electrodes, e.g., within a hand-piece, and 
are conveyed outward by an intense gas stream. 1,62 Depending on the type of carrier gas 
(i.e., argon or helium containing atmospheric pressured ambient air plasma), the energy 
supply for plasma generation and the type of plasma generation, the plasma may appear as 
a visible flame-like beam from a nozzle.1 In both directly and indirectly generated plasma, the 
plasma contains charged particles (electrons, ions), excited atoms and molecules (i.e., 
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singulett-oxygen), free radicals (atoms or molecules containing an unpaired electron), 
photons and electromagnetic fields, leading to the emission of visible UV or VUV radiation. 
The chemical composition and the physical characteristics of the generated plasma 
significantly depend on a number of variables such as pressure, gas mixture, design of the 
device, physical stimuli, and others. The reactive compounds, which become biochemically 
active, emerge either during the generation of the plasma in due course of interaction with 
molecules of the surrounding air, and/or with the medium, the bodily fluid, or the tissue to be 
treated.63-65 
In addition to the direct plasma effects due to the composition of the CAP at the effect site, 
there are also subsequent secondary actions within the tissue, based on radical formation 
generated by CAP, similar to physiologically generated radicals. Hydroxyl radicals (•OH) may 
act as second messengers in T-cell activation,66 and induce apoptosis.67 Nitrogen monoxide 
(NO) acts as a vasodilator, influences tissue oxygen metabolism,68 and can prevent 
excessive amplification of Th1 cells.69 NO and peroxynitrite (ONOO-) promote angiogenesis, 
influence cell proliferation and differentiation.70,71 These examples of reactive oxygen and 
nitrogen species are also expected in CAP or in interaction of plasma with fluids,72, 73 and 
could substantially contribute to generating the biological effects of CAP. The major 
difference between plasma species and endogenous radical production is the increased 
amounts of oxygen and nitrogen reactive species during CAP exposure. Although in 
endogenous metabolism, radicals are produced, increased generation of oxygen species can 
lead to direct cell damage.74,75 The effect of electrons and ions in generating radicals in CAPs 
are probably not necessarily of radical nature, but rather consequential reactions of the body 
following oxidative stress. Radicals, in particular, can exert ionizing effects on tissue 
components due to their tendency towards electron donation or uptake. Radical-driven 
reactions attack a variety of chemical bonds during this process.76 
Hydrogen peroxide can be considered a pharmacologically relevant oxidation product.77 The 
reactions following plasma use described above compare to the phenomena seen after the 
exposition of mononuclear blood cells to culture media, in that similar anti-proliferative and 
cytotoxic effects could be elicited by long-term CAP treatment of cell suspensions.78 This is in 
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line with demonstrable anti-microbial effects of saline solution73 and water79 following prior 
treatment with CAP. So far, it remains questionable whether the “induction of the phosphate 
starvation response regulon PhoP by Argon plasma”80 is a primary or secondary 
pharmacological effect.  
The enhanced oxygen radical reactivity has two causes: 
(a) In a thermodynamic capacity, oxygen radicals are relatively strong oxidants. 
(  is significantly larger than the standard potentials of hydrogen peroxide 
and oxygen: , .) 
(b) In a kinetic manner, oxygen radicals are, just like many other simply charged gas radicals, 
quite reactive, because they contribute to one-electron reactions, which in general can occur 
faster than complex redox reactions with oxidation number changes of more than ±1. Due to 
the known relationship between linear-free enthalpies, high constants for the speed of 
oxidation correlate with high standard potentials. Superoxide radicals bear a rather low 
oxidation potential (around –0.3 V), and therefore are only weak oxidants and rather strong 
reductive agents. Nevertheless, the reactions of the superoxide ion in water are quite fast, 
because protonation leads to generation of the hydrogen peroxide radical HO2, and the 
standard potentials for the formation of H2O2 or H2O are rather high: , 
. The risk potential of OH radicals is furthermore emphasized by the fact 
that they even attack seemingly inert substances, such as gold, liberating gold ions, rather 
than forming a stable surface of gold oxide, which could be expected following normal 
thermodynamic rules.81, 82 
 
Classification of CAPs as medical drug or medical device 
The classification of CAPs depends on its intended use. It is crucial to determine whether or 
not solely physically (thermal, such as in coagulation), or pharmacologically active substrates 
are being generated as part of the main effect. Even in the latter case, however, CAPs can 
2OH/H O
   2.813 VE 
2 2 2H O /H O
  1.763 VE 
2 2O /H O
   1.229 VE 
2 2 2HO /H O
   1.44 VE 
2 2HO /H O
   1.65 VE 
 7 
still be classified as medical device when used for cleaning of artificial surfaces, e.g. biofilm 
removal on dental implants.  
All therapeutic effects of CAP reported to date are mainly based on effects of radical-derived 
reactive products,73,74,83,84 which are associated with a pharmacological/immunological effect. 
Physical effects such as increased body temperature, electromagnetic fields, and (CAP 
source-dependent) UV or VUV radiation can potentially enhance these effects. However, 
therapeutic effects in healing of chronic wounds85 cannot be explained by physical effects 
alone. Moreover, the clinical course of chronic wound healing after the application of plasma 
in domestic animals and humans suggests that the plasma effect may trigger an intermediate 
phase of acute inflammation.86 The underlying immunological and biological mechanisms are 
not yet fully understood, but induction of integrins,87 NO,88 and increased phosphorylation of 
ß-Catenin89 may indicate pharmacological and immunological effects of CAPs. 
 
However, the complex composition of CAP and its generation within the plasma source at 
the time of application further corroborates its systematic classification within the classic drug 
category. In comparison with “classic” medical drugs, this may have the following 
consequences:  
- The CAP compounds cannot be prepared and stored in a carrier substrate in defined 
doses with detailed knowledge about the exact composition before application on a 
patient. 
- For CAP, storage times cannot be defined, as required for drugs or certain medical 
devices such as surgical or medical examination gloves. Instead, routine technical 
service and maintenance of the plasma-generating source will be required. 
- Newly generated plasma intended for medical use can be uniquely different from 
another plasma in terms of its composition, depending on the type of plasma 
generation, the carrier gas used and environmental conditions. Therefore, the actual 
plasma for each current use needs to be thoroughly described in terms of its active 
components. During each use, narrow margins of tolerance need to be defined and 
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followed. Quantifiable parameters of action are: energy application (J/m2), 
temperature, field strength, UV spectrum, gas uses, and, associated with these, 
radicals in plasma. However, due to technical limitations, accurate quantification of 
radicals is not currently feasible. Moreover, it is technically challenging to maintain the 
energy application constant for a particular plasma source. 
- Similar to a drug, CAPs intended for therapeutic application need to be composed of 
a defined content, which is unaltered by changes in environmental conditions, such 
as humidity of the ambient air. Therefore, plasma application needs to be 
independent of the surrounding atmosphere. 
 
Conclusion 
CAP as a new therapeutic option for chronic wounds or for neoplastic formations appears to 
be promising. Nevertheless, potentially deleterious long-term effects need to be ruled out. 
This applies particularly to mutagenic and carcinogenic risks of long-term plasma application. 
Therefore, before CAPs can safely be used in clinical applications for wound and skin 
treatment or treatment of tumors, it is imperative to further evaluate the interaction of living 
pro- and eukaryotic cells with CAP.  
Analysis of physical and pharmacological properties of CAP supports its classification as a 
drug, which is generated by use of a medical device directly at the point of therapeutic 
application. In contrast to conventional drugs, CAP and its biologically active compounds are 
generated at the time of application by use of a medical device. Therefore, the effective 
plasma itself, which is generated at the treatment site could be regarded as a local redox 
modulator, which stimulates the cells and thus represents an applied pharmacological 
principle. The mode of action of the locally generated CAP with its main active components – 
the different radicals – is pharmacological and not physical in nature.  
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